JNJ-77242113

· Janssen Pharmaceutical K.K.

Drug timelines are a Plus or Pro feature.

14 regulatory and trial events tracked for JNJ-77242113, covering 2025-02-03 to 2026-06-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

See pricing